Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6480603 | 0.99 | TDP1 (0.47) | TDP1L3MBTL1MAPK1ALDH1A1MAPT | |
| Hydrochloric Acid SCHEMBL6486019 | 0.99 | TDP1 (0.47) | TDP1L3MBTL1MAPK1ALDH1A1MAPT | |
| Hydrochloric Acid SCHEMBL6486010 | 0.99 | TDP1 (0.47) | TDP1L3MBTL1MAPK1ALDH1A1MAPT | |
| Hydrochloric Acid SCHEMBL6480613 | 0.99 | TDP1 (0.47) | TDP1L3MBTL1MAPK1ALDH1A1MAPT | |
| SCHEMBL6480671 | 0.89 | TDP1 (0.63) | TDP1ALDH1A1RAB9AGAA | |
| Hydrochloric Acid SCHEMBL6480674 | 0.88 | TDP1 (0.62) | TDP1ALDH1A1RAB9AGAA | |
| Hydrochloric Acid SCHEMBL6480666 | 0.88 | TDP1 (0.62) | TDP1ALDH1A1RAB9AGAA | |
| Hydrochloric Acid SCHEMBL6479201 | 0.84 | RAB9A (0.61) | ALDH1A1RAB9A | |
| Hydrochloric Acid SCHEMBL6486789 | 0.84 | RAB9A (0.61) | ALDH1A1RAB9A | |
| Hydrochloric Acid SCHEMBL6478621 | 0.82 | ALDH1A1 (0.53) | ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050043358-A1 | Aminoalcohol derivatives and their use as beta 3 adrenergic agonists | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2005-02-24 | — | — | US | disclosed |
| US-20020143034-A1 | Aminoalcohol derivatives and their use as beta 3 adrenergic agonists | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2002-10-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020143034-A1 | Aminoalcohol derivatives and their use as beta 3 adrenergic agonists | ADRB1, ADRB2, ADRB3 | TDP1 3342/4885L3MBTL1 2659/4885MAPK1 457/4885 |
| US-20050043358-A1 | Aminoalcohol derivatives and their use as beta 3 adrenergic agonists | ADRB2, ADRB1, ADRB3 | TDP1 3843/4885L3MBTL1 2835/4885MAPK1 921/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.